Recombinant Human DNAM-1

DNAX accessory molecule 1 (DNAM-1), is a tyrosine-phosphorylated signal-transducing molecule belonging to the immunoglobulin superfamily and participates in primary adhesion during cytotoxic T lymphocyte-mediated cytotoxicity. <sup<1
DNAM-1 is a functional glycoprotein expressed on immune cells, such as natural killer and T-cells. It is activated upon interaction with its biological ligands, the poliovirus receptor and nectin-2. Signaling cascades involving stimulation of DNAM-1 lead to various biological responses, including target cell lysis and immune cell activation. DNAM-1 appears to be an integral molecule in immune responses in cancer, allergic inflammatory disorders and autoimmune diseases.²

Fc Fusion Protein

ee vlwhtsvpfa enmslecvyp smgiltqvew fkigtqqdsi aifspthgmv irkpyaervy flnstmasnn mtlffrnase ddvgyyscsl ytypqgtwqk viqvvqsdsf eaavpsnshi vsepgknvtl tcqpqmtwpv qavrwekiqp rqidlltycn lvhgrnftsk fprqivsncs hgrwsvivip dvtvsdsgly rcylqasage netfvmrltv aegktdnhie grmdpkscdk thtcppcpap ellggpsvfl fppkpkdtlm isrtpevtcv vvdvshedpe vkfnwyvdgv evhnaktkpr eeqynstyrv vsvltvlhqd wlngkeykck vsnkalpapi ektiskakgq prepqvytlp psrdeltknq vsltclvkgf ypsdiavewe sngqpennyk ttppvldsdg sfflyskltv dksrwqqgnv fscsvmheal hnhytqksls lspgk

Glu19

Lyophilized

The predicted molecular weight of Recombinant Human DNAM-1 is Mr 53 kDa. However, the actual molecular weight as observed by migration on SDS-PAGE is Mr 75-80 kDa.

53

This recombinant protein was 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 with no calcium, magnesium, or preservatives.

This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.

Next Day Ambient

1. Phillips, JH. et al.(1996) Immunity. 4(6):573-81.
2. Levi-Schaffer, F. et al. (2008) Curr Opin Investig Drugs. 9(5):491-6.